The global demand for Cognitive Impairment Associated With Schizophrenia (CIAS) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline companies from advancing their products into Phase 3 or Phase 4.
Cognitive Impairment Associated With Schizophrenia (CIAS) Report Description
The 2019 pipeline study on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds.
The Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline guide presents information on all active drugs currently being developed for Cognitive Impairment Associated With Schizophrenia (CIAS). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Cognitive Impairment Associated With Schizophrenia (CIAS) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report includes
For each pipeline candidate, the following details are provided:
Reasons to Buy
The report will be delivered in 2 working days.
Cognitive Impairment Associated With Schizophrenia (CIAS) Report Description
The 2019 pipeline study on Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline compounds.
The Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline guide presents information on all active drugs currently being developed for Cognitive Impairment Associated With Schizophrenia (CIAS). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Cognitive Impairment Associated With Schizophrenia (CIAS) drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Cognitive Impairment Associated With Schizophrenia (CIAS) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline report includes
- An overview of Cognitive Impairment Associated With Schizophrenia (CIAS) disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline
- Company wise list of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline
- Mechanism of Action wise Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline
For each pipeline candidate, the following details are provided:
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
Reasons to Buy
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Table of Contents
1.1 List of Tables1.2 List of Figures
2. Global Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. Executive Summary
3.1 Cognitive Impairment Associated With Schizophrenia (CIAS) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline, H1- 2019
3.5 Mechanism of Action wise Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Candidates
4 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
4.1 Anvyl LLC Business Profile
4.2 Anvyl LLC Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
5.1 Astellas Pharma Inc Business Profile
5.2 Astellas Pharma Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
6.1 AstraZeneca Plc Business Profile
6.2 AstraZeneca Plc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
7.1 Autifony Therapeutics Ltd Business Profile
7.2 Autifony Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
8.1 Biogen Inc Business Profile
8.2 Biogen Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
9.1 Biomed SL Business Profile
9.2 Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
10.1 Boehringer Ingelheim GmbH Business Profile
10.2 Boehringer Ingelheim GmbH Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
11.1 Bristol-Myers Squibb Co Business Profile
11.2 Bristol-Myers Squibb Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
12.1 Cadent Therapeutics Business Profile
12.2 Cadent Therapeutics Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
13.1 Eli Lilly and Co Business Profile
13.2 Eli Lilly and Co Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
14.1 F. Hoffmann-La Roche Ltd Business Profile
14.2 F. Hoffmann-La Roche Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 Heptares Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
15.1 Heptares Therapeutics Ltd Business Profile
15.2 Heptares Therapeutics Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16 Intra-Cellular Therapies Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
16.1 Intra-Cellular Therapies Inc Business Profile
16.2 Intra-Cellular Therapies Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
17.1 Iproteos SL Business Profile
17.2 Iproteos SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
18.1 Pfizer Inc Business Profile
18.2 Pfizer Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
19.1 SK Biopharmaceuticals Co Ltd Business Profile
19.2 SK Biopharmaceuticals Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
20.1 Spherium Biomed SL Business Profile
20.2 Spherium Biomed SL Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
21 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
21.1 Suven Neurosciences Inc Business Profile
21.2 Suven Neurosciences Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments
22 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
22.1 Takeda Pharmaceutical Co Ltd Business Profile
22.2 Takeda Pharmaceutical Co Ltd Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments
23 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Pipeline Details
23.1 Vanda Pharmaceuticals Inc Business Profile
23.2 Vanda Pharmaceuticals Inc Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments
24. Latest Cognitive Impairment Associated With Schizophrenia (CIAS) Drug Pipeline Developments, 2019
25. Appendix
25.1 About Us
25.2 Sources and Methodology
25.3 Contact Information
Companies Mentioned
- Anvyl LLC
- Astellas Pharma Inc
- AstraZeneca Plc
- Autifony Therapeutics Ltd
- Biogen Inc
- Biomed SL
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cadent Therapeutics
- Eli Lilly and Co
- F. Hoffmann-La Roche Ltd
- Heptares Therapeutics Ltd
- Intra-Cellular Therapies Inc
- Iproteos SL
- Pfizer Inc
- SK Biopharmaceuticals Co Ltd
- Spherium Biomed SL
- Suven Neurosciences Inc
- Takeda Pharmaceutical Co Ltd
- Vanda Pharmaceuticals Inc
